| Dr Jil M Johnson, DO | |
|
3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 | |
| (503) 418-4500 | |
| (503) 494-1678 |
| Full Name | Dr Jil M Johnson |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 19 Years |
| Location | 3181 Sw Sam Jackson Park Rd, Portland, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174763064 | NPI | - | NPPES |
| 8551319 | Medicaid | WA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tuality Community Hospital | Hillsboro, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Health And Sciences University/university Medical Group | 4880760107 | 1485 |
| Tuality Medical Group Llc | 7416173414 | 245 |
News Archive
The leading Asia-Pacific biotech specialist CRO Novotech is again collaborating with the prestigious biotech and pharma news platform Endpoints News. This webinar focusses on how to advance oncology clinical trials in the Asia-Pacific which is currently attracting 10,000 oncology studies.
The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication - and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.
Some small business owners remain wary of a health law they do not yet clearly understand, The Kansas City Star reports. "Employers with 50 or more employees know this: The new law has employee coverage mandates looming for them in 2014. Employers with fewer than 50 employees will escape the coverage mandate. But they're not resting easy." Business expect costs to increase by between 6 and 40 percent in 2011, and many wonder whether they will be able to continue to afford subsidizing their employees' insurance coverage (Stafford, 9/6).
Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
› Verified 4 days ago
| Entity Name | University Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376709535 PECOS PAC ID: 4880760107 Enrollment ID: O20080910000013 |
News Archive
The leading Asia-Pacific biotech specialist CRO Novotech is again collaborating with the prestigious biotech and pharma news platform Endpoints News. This webinar focusses on how to advance oncology clinical trials in the Asia-Pacific which is currently attracting 10,000 oncology studies.
The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication - and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.
Some small business owners remain wary of a health law they do not yet clearly understand, The Kansas City Star reports. "Employers with 50 or more employees know this: The new law has employee coverage mandates looming for them in 2014. Employers with fewer than 50 employees will escape the coverage mandate. But they're not resting easy." Business expect costs to increase by between 6 and 40 percent in 2011, and many wonder whether they will be able to continue to afford subsidizing their employees' insurance coverage (Stafford, 9/6).
Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
› Verified 4 days ago
| Entity Name | Tuality Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073929782 PECOS PAC ID: 7416173414 Enrollment ID: O20140729000238 |
News Archive
The leading Asia-Pacific biotech specialist CRO Novotech is again collaborating with the prestigious biotech and pharma news platform Endpoints News. This webinar focusses on how to advance oncology clinical trials in the Asia-Pacific which is currently attracting 10,000 oncology studies.
The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication - and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.
Some small business owners remain wary of a health law they do not yet clearly understand, The Kansas City Star reports. "Employers with 50 or more employees know this: The new law has employee coverage mandates looming for them in 2014. Employers with fewer than 50 employees will escape the coverage mandate. But they're not resting easy." Business expect costs to increase by between 6 and 40 percent in 2011, and many wonder whether they will be able to continue to afford subsidizing their employees' insurance coverage (Stafford, 9/6).
Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jil M Johnson, DO 3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 Ph: (503) 418-4500 | Dr Jil M Johnson, DO 3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 Ph: (503) 418-4500 |
News Archive
The leading Asia-Pacific biotech specialist CRO Novotech is again collaborating with the prestigious biotech and pharma news platform Endpoints News. This webinar focusses on how to advance oncology clinical trials in the Asia-Pacific which is currently attracting 10,000 oncology studies.
The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication - and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.
Some small business owners remain wary of a health law they do not yet clearly understand, The Kansas City Star reports. "Employers with 50 or more employees know this: The new law has employee coverage mandates looming for them in 2014. Employers with fewer than 50 employees will escape the coverage mandate. But they're not resting easy." Business expect costs to increase by between 6 and 40 percent in 2011, and many wonder whether they will be able to continue to afford subsidizing their employees' insurance coverage (Stafford, 9/6).
Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
› Verified 4 days ago
Dr. Rachel L Gutfreund, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 10101 Se Main St Ste 3001, Portland, OR 97216 Phone: 503-261-4423 Fax: 503-261-4424 | |
John Gilbert Buckmaster, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-4200 | |
Darlene J Dodson, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 9205 Sw Barnes Rd Fl 3, Portland, OR 97225 Phone: 503-216-3388 | |
Antonio E Frias, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-418-4200 Fax: 503-494-4473 | |
Sig-linda Jacobson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5006 Sw Martha St, Portland, OR 97221 Phone: 503-806-7854 | |
Laila Raad Sillay, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 9555 Sw Barnes Rd Ste 360, Portland, OR 97225 Phone: 503-445-0590 | |
Edward Paul Kirk, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-4500 |